MORTIMER IAN — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

MORTIMER IAN is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $21.30M.

Profile

MORTIMER IAN

Ian Mortimer is the President and CEO of Xenon Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. He has held multiple roles within the company, including interim CFO, and has been involved in advancing its product pipeline.

RoleInsider
Notability50/100

Board memberships

Awards & honors

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-03-14XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]7.3K$55.23$404K
2026-03-14XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]12.5K—
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]11.3K$60.11$677K
2026-03-11XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]20.0K—
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]65.0K$62.06$4.03M
2026-03-11XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]65.0K$9.44$614K
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]61.7K$60.08$3.70M
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]43.3K$59.26$2.57M
2026-03-11XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]105.0K$4.75$499K
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]2.4K$61.26$150K
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]10.1K$60.47$609K
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]12.5K$59.50$743K
2026-03-11XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]25.0K$3.10$78K
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]21.5K$60.49$1.30M
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]31.7K$59.88$1.90M
2026-03-11XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]21.8K$58.81$1.28M
2026-03-11XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]75.0K$8.40$630K
2026-01-02XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]2.1K$44.93$93K
2026-01-02XENEXenon Pharmaceuticals Inc.S — Open-market sale [10b5-1]37.9K$44.40$1.68M
2026-01-02XENEXenon Pharmaceuticals Inc.M — Option exercise [10b5-1]40.0K$7.49$300K

Frequently Asked Questions

Who is MORTIMER IAN?

Ian Mortimer is the President and CEO of Xenon Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. He has held multiple roles within the company, including interim CFO, and has been involved in advancing its product pipeline.…

Has MORTIMER IAN been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 18 open-market sales ($21.30M) across all tracked filings.

Where can I see all of MORTIMER IAN's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live MORTIMER IAN profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.